Citadel Advisors’s Agile Therapeutics AGRX Stock Holding History

Citadel Advisors’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-13	Closed	-$25K	–	15173
2021 Q3	$25K	Sell	13 -33	-72%	-$74.7K	﹤0.01%	13618
2021 Q2	$123K	Sell	46 -6	-12%	-$19.8K	﹤0.01%	12722
2021 Q1	$218K	Buy	52 +24	+86%	+$130K	﹤0.01%	11532
2020 Q4	$160K	Buy	28 +9	+47%	+$53K	﹤0.01%	9906
2020 Q3	$115K	Sell	19 -3	-14%	-$17.2K	﹤0.01%	9192
2020 Q2	$122K	Hold	22	–	–	﹤0.01%	8876
2020 Q1	$81K	Buy	22 +5	+29%	+$28.7K	﹤0.01%	8784
2019 Q4	$86K	Buy	+17	New	+$59.4K	﹤0.01%	8602

Other funds holding AGRX

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

Citadel Advisors's AGRX Position: Q1 2024 in Review

Citadel Advisors sold out of Agile Therapeutics (AGRX) in Q1 2024, closing a stake of 19,247 shares — an estimated $37.5K sold.

Citadel Advisors first reported a position in AGRX in Q4 2015 and held it in 13 quarters. The position peaked at $408K in Q1 2021. 1 fund tracked by Wall St. Rank holds AGRX as of Q1 2024.

Citadel Advisors reported no remaining Agile Therapeutics position as of Q1 2024 after selling out during the quarter.
Citadel Advisors sold 19,247 Agile Therapeutics shares in Q1 2024, an estimated $37.5K.
Citadel Advisors first reported a position in Agile Therapeutics in Q4 2015 and held it in 13 quarters.
Citadel Advisors's Agile Therapeutics position peaked at $408K in Q1 2021.
1 fund tracked by Wall St. Rank held Agile Therapeutics as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.